Acessibilidade / Reportar erro
This erratum corrects:

Erratum

Arq Neuropsiquiatr. 2019;77(7):509-520

Consensus of the Brazilian Headache Society on the treatment of chronic migraine

DOI: http://dx.doi.org/10.1590/0004-282x20190078

The table 5:

Table 5 Oral drugs evaluated in the treatment of chronic migraine in adults: evidence of efficacy, class of recommendation, recommended doses and risk categories regarding use during pregnancy and lactation.

Drug Evidence Recommendation Dose (mg/day) Risk during pregnancy* Risk during lactation** References
Neuromodulators
Topiramate I A 50-200 D L3 62, 64-66, 70
Valproate II B 500-2000 X L2 71
Gabapentin II B 900-1800 C L2 72
Pregabalin III C 125-450 C L2 73
Zonisamide III C 50-200 D L5 74
Beta-blockers
Atenolol III C 50-200 C L3 75
Tricyclics
Amitriptyline II C 50-100 C L2 76
Calcium channel blockers
Flunarizine III C 10 C L5 77
Miscellaneous
Tizanidine II B fev/24 C L3 78

Should be:

Table 5 Oral drugs evaluated in the treatment of chronic migraine in adults: evidence of efficacy, class of recommendation, recommended doses and risk categories regarding use during pregnancy and lactation.

Drug Evidence Recommendation Dose (mg/day) Risk during pregnancy* Risk during lactation** References
Neuromodulators
Topiramate I A 50-200 D L3 62, 64-66, 70
Valproate II B 500-2000 X L2 71
Gabapentin II B 900-1800 C L2 72
Pregabalin III C 125-450 C L2 73
Zonisamide III C 50-200 D L5 74
Beta-blockers
Atenolol III C 50-200 C L3 75
Tricyclics
Amitriptyline II C 50-100 C L2 76
Calcium channel blockers
Flunarizine III C 10 C L5 77
Miscellaneous
Tizanidine II B 2-24 C L3 78

Publication Dates

  • Publication in this collection
    24 Oct 2019
  • Date of issue
    Oct 2019
Academia Brasileira de Neurologia - ABNEURO R. Vergueiro, 1353 sl.1404 - Ed. Top Towers Offices Torre Norte, 04101-000 São Paulo SP Brazil, Tel.: +55 11 5084-9463 | +55 11 5083-3876 - São Paulo - SP - Brazil
E-mail: revista.arquivos@abneuro.org